Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00871481|
Recruitment Status : Completed
First Posted : March 30, 2009
Last Update Posted : April 19, 2017
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Melanoma Stage IV Melanoma||Biological: ipilimumab Drug: cyclophosphamide Procedure: biopsy Biological: aldesleukin Other: immunohistochemistry staining method Genetic: polymerase chain reaction Other: immunoenzyme technique Biological: therapeutic cytotoxic T lymphocytes||Phase 1 Phase 2|
I. Evaluate the safety and efficacy of adoptively transferred cytotoxic lymphocytes (CTL) targeting melanoma tumors combined with anti-CTLA4.
II. Evaluate the influence of anti-CTLA4 (ipilimumab) on the duration of in vivo persistence and anti-tumor efficacy achieved following adoptive transfer of antigen-specific CTL.
I. Evaluate the influence of anti-CTLA4 on the induction of T cells to non-targeted tumor-associated antigens (antigen-spreading) following adoptive transfer antigen-specific CTL, and the correlation of these responses with clinical outcome.
Patients receive cyclophosphamide intravenously (IV) on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin subcutaneously (SC) twice daily (BID) on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma|
|Study Start Date :||February 2009|
|Primary Completion Date :||September 2013|
|Study Completion Date :||October 2013|
Experimental: Treatment (laboratory-treated T cells and ipilimumab)
Patients receive cyclophosphamide IV on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin SC BID on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
Other Names:Drug: cyclophosphamide
Other Names:Procedure: biopsy
Optional correlative studies
Other Name: biopsiesBiological: aldesleukin
Other Names:Other: immunohistochemistry staining method
Other Name: immunohistochemistryGenetic: polymerase chain reaction
Other Name: PCROther: immunoenzyme technique
Other Name: immunoenzyme techniquesBiological: therapeutic cytotoxic T lymphocytes
Other Name: therapeutic CTLs
- Numeric frequency and functional persistence of transferred CTL [ Time Frame: Up to 6 months post-infusion ]Determined using peptide major histocompatibility complex (MHC)-tetramer analysis or specific CDR3 T-cell-receptor (TCR) quantitative polymerase chain reaction (PCR) of transferred CTL if necessary. The function of transferred CTL will be determined by intracellular cytokine staining of tetramer+ CD8+ cells following in vitro stimulation.
- Toxicity assessment of study treatment, assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 [ Time Frame: Up to 6 months post-infusion ]
- Responses to non-targeted T cell antigens [ Time Frame: Up to 1 year following T cell infusion and/or at the time of observed partial or complete clinical response ]Blood samples taken will be analyzed for the induction of non-targeted T cell responses. Two approaches will be used: tetramer analysis and enzyme-linked immunosorbent spot (ELISPOT) assay.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00871481
|United States, Washington|
|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|
|Seattle, Washington, United States, 98109|
|Principal Investigator:||Aude Chapuis||Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|